Tom Bradley offers a lesson in improving hiring processes. As formerly rock-solid revenue streams dry up, many life sciences companies are paying closer than ever scrutiny to operating costs. With people costs...
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh